ImmunityBio, Inc. and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biopharma Companies

In the competitive landscape of biopharmaceuticals, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Amphastar Pharmaceuticals, Inc. and ImmunityBio, Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, Amphastar's SG&A expenses grew steadily, peaking at approximately $80 million in 2023, marking a 99% increase from 2014. In contrast, ImmunityBio's spending exhibited more volatility, with a dramatic spike in 2015, reaching over $226 million, before stabilizing around $130 million in recent years. This fluctuation suggests a period of aggressive expansion or restructuring.

These trends highlight the differing strategies: Amphastar's consistent growth versus ImmunityBio's more dynamic spending. Investors and analysts can glean insights into each company's operational focus and market positioning by examining these financial trajectories.